Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Refractory/Relapse Neuroblastoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroendocrine Tumors 1Neoplasms, Squamous Cell 1Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoma 1Lung Neoplasms 1Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 27Oxaliplatin 24Paclitaxel 22Fluorouracil 21Carboplatin 18Leucovorin 16Cisplatin 16Capecitabine 16Radiotherapy 15Nivolumab 12Drug Therapy 12Radiation 10Trastuzumab 9Surgical Procedures, Operative 8Immunotherapy 8Magnetic Resonance Spectroscopy 7Esophagectomy 7Blood Specimen Collection 7Taxes 6tislelizumab 5durvalumab 5Surveys and Questionnaires 5Specimen Handling 5Radiotherapy, Intensity-Modulated 5Irinotecan 5Immune Checkpoint Inhibitors 5Docetaxel 5Bevacizumab 5Ramucirumab 4Fluorodeoxyglucose F18 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Biological Products × 1 year × Clear all
NCT04908111 2026-04-06

A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1

Cancer Research UK

Phase 1/2 Suspended
15 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms, Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡